We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why
Read MoreHide Full Article
Key Takeaways
Collegium Pharmaceutical expanded its ADHD portfolio with the Azstarys acquisition and raised 2026 guidance.
COLL expects 2026 product revenues of $865M-$895M after lifting prior guidance following the acquisition.
Collegium Pharmaceutical's Jornay PM posted a record 206,000-plus prescriptions, supporting growth momentum.
Shares of Collegium Pharmaceutical (COLL - Free Report) have gained around 12% over the past three months, driven by growing investor confidence in the company's expanding commercial portfolio, durable revenue base and long-term growth strategy.
Jornay PM Continues to Drive COLL’s ADHD Franchise Growth
A key driver of this momentum has been the continued strong performance of Collegium Pharmaceutical's attention deficit hyperactivity disorder (ADHD) franchise, led by Jornay PM. During the first quarter of 2026, Jornay PM recorded more than 206,000 prescriptions, up 14% year over year, reflecting strong prescription growth and increasing physician adoption. Sales of the drug increased 36% year over year in the quarter, driven by successful commercial execution and increased market penetration. As a differentiated evening-dosed ADHD therapy, Jornay PM has emerged as the company's fastest-growing commercial product, reinforcing confidence in its long-term growth potential.
Year to date, shares of COLL have lost 21.7% compared with the industry’s 5.3% decline.
Image Source: Zacks Investment Research
Azstarys Acquisition Strengthens COLL’s Growth Outlook
Investor sentiment was strengthened following the completion of Collegium Pharmaceutical's acquisition of Azstarys from Corium Therapeutics last month. The transaction represents a significant strategic milestone, enhancing the company's position in the ADHD market while expanding its central nervous system portfolio. Azstarys is the first and only treatment with both immediate-release and long-acting medicines in a single capsule approved for the treatment of ADHD in patients aged six years and older. The drug complements the company's existing Jornay PM franchise and broadens its treatment offerings for patients.
The acquisition is expected to be immediately accretive to earnings, prompting Collegium Pharmaceutical to raise its 2026 financial guidance. COLL expects 2026 product revenues to be in the range of $865-$895 million compared with prior guidance of $805 to $825 million. With patent protection extending through 2037, Azstarys is expected to meaningfully expand Collegium Pharmaceutical's revenue base and enhance long-term cash flow generation.
Beyond its growing ADHD franchise, Collegium Pharmaceutical continues to benefit from a well-established pain management business that provides a stable, recurring source of revenues and cash flow. COLL’s pain portfolio includes Xtampza ER, Belbuca, Nucynta ER, Nucynta IR and Symproic, which collectively address chronic and acute pain, as well as opioid-induced constipation.
Collegium Pharmaceutical, Inc. Price and Consensus
Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss per share of 88 cents to earnings of 6 cents per share. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents. IMCR shares have lost 8.5% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 46.66%.
Over the past 60 days, loss per share estimates for Amarin Corporation have narrowed from $15.20 to 65 cents for 2026. Over the same period, estimates for loss per share have also narrowed from $13.00 to 51 cents for 2027. AMRN shares have risen 14.6% year to date.
Amarin Corporation’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 50.02%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have increased to $3.02 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.92 from $2.91. LQDA shares have gained 131.1% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
View the Zacks #1 Rank List
Image: Bigstock
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why
Key Takeaways
Shares of Collegium Pharmaceutical (COLL - Free Report) have gained around 12% over the past three months, driven by growing investor confidence in the company's expanding commercial portfolio, durable revenue base and long-term growth strategy.
Jornay PM Continues to Drive COLL’s ADHD Franchise Growth
A key driver of this momentum has been the continued strong performance of Collegium Pharmaceutical's attention deficit hyperactivity disorder (ADHD) franchise, led by Jornay PM. During the first quarter of 2026, Jornay PM recorded more than 206,000 prescriptions, up 14% year over year, reflecting strong prescription growth and increasing physician adoption. Sales of the drug increased 36% year over year in the quarter, driven by successful commercial execution and increased market penetration. As a differentiated evening-dosed ADHD therapy, Jornay PM has emerged as the company's fastest-growing commercial product, reinforcing confidence in its long-term growth potential.
Year to date, shares of COLL have lost 21.7% compared with the industry’s 5.3% decline.
Image Source: Zacks Investment Research
Azstarys Acquisition Strengthens COLL’s Growth Outlook
Investor sentiment was strengthened following the completion of Collegium Pharmaceutical's acquisition of Azstarys from Corium Therapeutics last month. The transaction represents a significant strategic milestone, enhancing the company's position in the ADHD market while expanding its central nervous system portfolio. Azstarys is the first and only treatment with both immediate-release and long-acting medicines in a single capsule approved for the treatment of ADHD in patients aged six years and older. The drug complements the company's existing Jornay PM franchise and broadens its treatment offerings for patients.
The acquisition is expected to be immediately accretive to earnings, prompting Collegium Pharmaceutical to raise its 2026 financial guidance. COLL expects 2026 product revenues to be in the range of $865-$895 million compared with prior guidance of $805 to $825 million. With patent protection extending through 2037, Azstarys is expected to meaningfully expand Collegium Pharmaceutical's revenue base and enhance long-term cash flow generation.
Beyond its growing ADHD franchise, Collegium Pharmaceutical continues to benefit from a well-established pain management business that provides a stable, recurring source of revenues and cash flow. COLL’s pain portfolio includes Xtampza ER, Belbuca, Nucynta ER, Nucynta IR and Symproic, which collectively address chronic and acute pain, as well as opioid-induced constipation.
Collegium Pharmaceutical, Inc. Price and Consensus
Collegium Pharmaceutical, Inc. price-consensus-chart | Collegium Pharmaceutical, Inc. Quote
COLL’s Zacks Rank & Other Stocks to Consider
Collegium Pharmaceutical currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are Immunocore (IMCR - Free Report) , Amarin Corporation (AMRN - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss per share of 88 cents to earnings of 6 cents per share. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents. IMCR shares have lost 8.5% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 46.66%.
Over the past 60 days, loss per share estimates for Amarin Corporation have narrowed from $15.20 to 65 cents for 2026. Over the same period, estimates for loss per share have also narrowed from $13.00 to 51 cents for 2027. AMRN shares have risen 14.6% year to date.
Amarin Corporation’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 50.02%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have increased to $3.02 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.92 from $2.91. LQDA shares have gained 131.1% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.